JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

Search

Merck & Co Inc.

Cerrado

SectorSalud

80.91 1.26

Resumen

Variación precio

24h

Actual

Mínimo

79.61

Máximo

81.12

Métricas clave

By Trading Economics

Ingresos

1.3B

5.1B

Ventas

-95M

16B

P/B

Media del Sector

12.218

40.048

BPA

2.22

Rentabilidad por dividendo

3.68

Margen de beneficio

32.745

Empleados

73,000

EBITDA

386M

7.3B

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+28.55% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

3.68%

2.45%

Próximas Ganancias

30 oct 2025

Fecha Próximo Dividendo

7 oct 2025

Próxima Fecha de Ex Dividendo

15 sept 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-1.6B

211B

Apertura anterior

79.65

Cierre anterior

80.91

Noticias sobre sentimiento de mercado

By Acuity

33%

67%

109 / 374 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Bearish Evidence

Merck & Co Inc. Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

29 jul 2025, 10:45 UTC

Ganancias

Merck & Co. to Lay Off Workers, Reduce Real Estate to Invest in New Products

29 jul 2025, 11:13 UTC

Ganancias

Merck Stock Falls After Earnings on Revenue Miss and Job Cuts -- Barrons.com

29 jul 2025, 10:45 UTC

Ganancias

Merck Stock Falls After Earnings on Revenue Miss and Job Cuts -- Barrons.com

29 jul 2025, 10:30 UTC

Ganancias

Merck: Updated FY Adj EPS Outlook Does Not Include Anticipated Impact of Verona Pharma Acquisition >MRK

29 jul 2025, 10:30 UTC

Ganancias

Merck: $200M of Costs Related to Impact of Tariffs in FY Outlook Unchanged Vs Previous Guidance Pending Outcome of Additional Potential Government Actions >MRK

29 jul 2025, 10:30 UTC

Ganancias

Merck: As Part of Initiative, Approved New Restructuring Program in Which Co. Expects to Eliminate Certain Administrative, Sales and R&D Positions >MRK

29 jul 2025, 10:30 UTC

Ganancias

Merck: Updated FY Adj EPS Outlook Includes Revised Negative Impact of Foreign Exchange of About 15c/Shr >MRK

29 jul 2025, 10:30 UTC

Ganancias

Merck: For Latest 2Q, Recorded Charges of $649M Related to Restructuring Program >MRK

29 jul 2025, 10:30 UTC

Ganancias

Merck Narrows FY View To Sales $64.3B-$65.3B Vs Prior View $64.1B-$65.6B >MRK

29 jul 2025, 10:30 UTC

Ganancias

Merck: Expect Actions Under Restructuring Program to Result in Annual Cost Savings of About $1.7B, Which Will Be Substantially Realized by End of 2027 >MRK

29 jul 2025, 10:30 UTC

Ganancias

Merck: Will Continue to Hire Employees Into New Roles Across Strategic Growth Areas of the Business >MRK

29 jul 2025, 10:30 UTC

Ganancias

Merck: Restructuring Program Is Part of the Multiyear Optimization Initiative Expected to Achieve $3B in Annual Cost Savings by End of 2027 >MRK

29 jul 2025, 10:30 UTC

Ganancias

Merck Sees Cumulative Pretax Costs Related to Program to Be About $3B >MRK

29 jul 2025, 10:30 UTC

Ganancias

Merck Launching New Multiyear Optimization Initiative to Enable Transformation of CO's Portfolio by Generating Expected $3B in Annual Cost Savings From Productivity Actions >MRK

29 jul 2025, 10:30 UTC

Ganancias

Merck: Savings Will Be Fully Reinvested to Support New Product Launches and Pipeline Across Multiple Therapeutic Areas >MRK

29 jul 2025, 10:30 UTC

Ganancias

Merck: Will Reduce Global Real-Estate Footprint and Continue to Optimize Manufacturing Network, Aligning Geography of Global Manufacturing to Co's Customers >MRK

29 jul 2025, 10:30 UTC

Ganancias

Merck 2Q Winrevair Sales $336M >MRK

29 jul 2025, 10:30 UTC

Ganancias

Merck 2Q Keytruda Sales Up 9% >MRK

29 jul 2025, 10:30 UTC

Ganancias

Merck: Lower Gardasil/Gardasil 9 and Januvia/Janumet Sales Primarily Due to Lower Demand in China >MRK

29 jul 2025, 10:30 UTC

Ganancias

Merck 2Q Gardasil/Gardasil 9 Sales Down 55% >MRK

29 jul 2025, 10:30 UTC

Ganancias

Merck 2Q Gardasil/Gardasil 9 Sales $1.13B >MRK

29 jul 2025, 10:30 UTC

Ganancias

Merck 2Q Animal Health Sales Up 11% >MRK

29 jul 2025, 10:30 UTC

Ganancias

Merck 2Q Pharmaceutical Sales Down 2% >MRK

29 jul 2025, 10:30 UTC

Ganancias

Merck 2Q Januvia/Janumet Sales Down 1% >MRK

29 jul 2025, 10:30 UTC

Ganancias

Merck 2Q Sales $15.81B >MRK

29 jul 2025, 10:30 UTC

Ganancias

Merck 2Q Pharmaceutical Sales $14.05B >MRK

29 jul 2025, 10:30 UTC

Ganancias

Merck 2Q Animal Health Sales $1.65B >MRK

29 jul 2025, 10:30 UTC

Ganancias

Merck 2Q Keytruda Sales $7.96B >MRK

29 jul 2025, 10:30 UTC

Ganancias

Merck 2Q Animal Health Sales Up 11% >MRK

29 jul 2025, 10:30 UTC

Ganancias

Merck 2Q EPS $1.76 >MRK

Comparación entre iguales

Cambio de precio

Merck & Co Inc. Esperado

Precio Objetivo

By TipRanks

28.55% repunte

Estimación a 12 meses

Media 101.93 USD  28.55%

Máximo 141 USD

Mínimo 82 USD

De acuerdo con 16 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Merck & Co Inc. Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

16 ratings

9

Comprar

7

Mantener

0

Vender

Puntuación técnica

By Trading Central

76.03 / 83.28Soporte y Resistencia

Corto Plazo

Bearish Evidence

Medio plazo

Bearish Evidence

Largo Plazo

Bearish Evidence

Sentimiento

By Acuity

109 / 374 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Merck & Co Inc.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. vIt has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. It also has licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.